Sio Gene Therapies (NASDAQ: AXGT)
Some price data may be temporarily unavailable.
Sio Gene Therapies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sio Gene Therapies Company Info
Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focuses on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis, such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in New York, NY.
News & Analysis
2 Under-the-Radar Biotech Stocks You'll Wish You Didn't Ignore
These underappreciated biotechnology start-ups could turn heads one day -- but not yet.
Is Axovant Gene Therapies a Buy?
The small-cap biopharma started 2019 with a rising stock price and a new focus on gene therapies, but it's been a rocky transition.
Here's Why Axovant Gene Therapies Dropped as Much as 16.6% Today
The biopharma is wisely taking advantage of its lofty stock price to raise capital through a share offering.
Here's Why Axovant Gene Therapies Rocketed Higher Today
Investors are excited about new clinical results suggesting the small-cap biopharma is on to something big.
Here's Why Axovant Sciences Lost as Much as 29.2% Today
The biopharma's wild year continues with another clinical failure, but it won't have much impact on the company's future.
Here's Why Axovant Sciences Fell as Much as 21.3% Today
The meteoric rise in recent weeks is proving unsustainable.
Why Xunlei, Griffon, and Axovant Sciences Slumped Today
Find out how these stocks got smacked down the hardest.
3 Drug Stocks That Soared This Week: Are They Buys?
Can these red-hot drug stocks keep the momentum going?
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.